Rhythm Pharmaceuticals Files 8-K on Operations
Ticker: RYTM · Form: 8-K · Filed: Nov 5, 2024 · CIK: 1649904
| Field | Detail |
|---|---|
| Company | Rhythm Pharmaceuticals, Inc. (RYTM) |
| Form Type | 8-K |
| Filed Date | Nov 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financial-reporting
TL;DR
Rhythm Pharma dropped an 8-K, check it for the latest on their financials.
AI Summary
Rhythm Pharmaceuticals, Inc. filed an 8-K on November 5, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing serves as an official update to the SEC regarding Rhythm Pharmaceuticals' financial status and operational results, which is crucial for investors to monitor the company's performance.
Risk Assessment
Risk Level: low — The filing is a standard regulatory report and does not inherently contain new risks or negative information.
Key Players & Entities
- Rhythm Pharmaceuticals, Inc. (company) — Registrant
- November 5, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Boston, MA (location) — Address of principal executive offices
FAQ
What specific financial results are being reported in this 8-K?
The provided text indicates the filing pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific figures within this excerpt.
When was this 8-K filing submitted?
The filing was submitted on November 5, 2024.
What is the principal business address of Rhythm Pharmaceuticals, Inc.?
The principal executive offices are located at 222 Berkeley Street, 12th Floor, Boston, MA 02116.
What is the IRS Employer Identification Number for Rhythm Pharmaceuticals, Inc.?
The IRS Employer Identification Number is 46-2159271.
What is the SIC code for Rhythm Pharmaceuticals, Inc.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-11-05 16:02:20
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share RYTM The Nasdaq
Filing Documents
- tm2427018d1_8k.htm (8-K) — 24KB
- tm2427018d1_ex99-1.htm (EX-99.1) — 124KB
- 0001104659-24-114304.txt ( ) — 334KB
- rytm-20241105.xsd (EX-101.SCH) — 3KB
- rytm-20241105_lab.xml (EX-101.LAB) — 33KB
- rytm-20241105_pre.xml (EX-101.PRE) — 22KB
- tm2427018d1_8k_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 5, 2024, Rhythm Pharmaceuticals, Inc. (the "Company") announced its financial results for the quarter ended September 30, 2024. The full text of the press release issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following Exhibit 99.1 relates to Item 2.02, and shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated November 5, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RHYTHM PHARMACEUTICALS, INC. Date: November 5, 2024 By: /s/ Hunter Smith Hunter Smith Chief Financial Officer